These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 4803612)

  • 21. [Scleromyxedema Arndt-Gottron: a paraproteinemic disease].
    Piper W; Hardmeier T; Schäfer E
    Schweiz Med Wochenschr; 1967 Jul; 97(26):829-38. PubMed ID: 5613452
    [No Abstract]   [Full Text] [Related]  

  • 22. [Thymoma with immune deficiency, erythroblastopenia monoclonal paraprotein and bone marrow plasmacytosis].
    Lemanager J; Tanguy A; Bernard Y
    Nouv Presse Med; 1973 May; 2(20):1374. PubMed ID: 4763030
    [No Abstract]   [Full Text] [Related]  

  • 23. [Thymoma with immune deficiency, erythroblastopenia monoclonal paraprotein and bone marrow plasmacytosis].
    Lemenager J; Tanguy A; Bernard Y
    Nouv Presse Med; 1973 May; 2(20):1374. PubMed ID: 4715921
    [No Abstract]   [Full Text] [Related]  

  • 24. Systemic sclerosis sine scleroderma: is it always the same disease? Report of three patients and discussion.
    Slobodin G; Rosner I; Rozenbaum M; Naschitz JE; Zuckerman E; Yeshurun D
    Rheumatol Int; 2002 Aug; 22(4):170-2. PubMed ID: 12172958
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Demonstration of antinuclear factors using indirect immunofluorescence in scleroderma patients].
    Nebe H; Blume N
    Dermatol Monatsschr; 1971 Jan; 157(1):27-31. PubMed ID: 4938251
    [No Abstract]   [Full Text] [Related]  

  • 26. [Immunochemical determination of serum albumin, transferrin, IgG, IgA and IgM].
    Weeke B
    Ugeskr Laeger; 1969 Aug; 131(34):1423-8. PubMed ID: 5356447
    [No Abstract]   [Full Text] [Related]  

  • 27. [Evaluation of immunological processes in expert testimony regarding disability in rheumatologic diseases].
    Morozova RZ; Pentiuk AA
    Vrach Delo; 1980 Mar; (3):58-60. PubMed ID: 7376615
    [No Abstract]   [Full Text] [Related]  

  • 28. [The immunophysiological and immunopathological aspects of scleroderma systematica: fundamental and clinical aspects].
    Khitrov AN; Gracheva TS; Isaeva MA; Grishina TI; Shoenfeld Y; Velichkovskiĭ BT; Suchkov SV
    Patol Fiziol Eksp Ter; 2007; (1):21-7. PubMed ID: 17526213
    [No Abstract]   [Full Text] [Related]  

  • 29. [Significance of histopathologic analysis of skin lesions in scleromyxedema. Light microscopy, electron microscopy, immunohistochemistry and immunofluorescence microscopy].
    Krajnc I; Vizjak A; Hvala A; Jurcic V; Rozman B
    Acta Med Austriaca; 1998; 25(3):109-12. PubMed ID: 9816405
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Progressive scleroderma].
    Schmitz-Moormann P; Seybold D
    Med Welt; 1971 Mar; 13():487-90. PubMed ID: 5563470
    [No Abstract]   [Full Text] [Related]  

  • 31. [Scleroderma renal crisis. 7 cases and review of the literature].
    Bonnet F; Longy-Boursier M; Aparicio M; Morlat P; Doutre MS; Conri C; Pellegrin JL; Leng B; Mercie P
    Ann Med Interne (Paris); 1998 Sep; 149(5):243-50. PubMed ID: 9791556
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ["Deep scleroderma" or diffuse fibromatous scleroderma. A case-report of uncertain nosologic classification (author's transl)].
    Herreman G; Huet D; Mundler B; Tamisier JN; Blum F; Wechsler J; Ferme I
    Sem Hop; 1982 May; 58(20):1225-8. PubMed ID: 6285507
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-annexin V antibodies and digital ischemia in patients with scleroderma.
    Sugiura K; Muro Y
    J Rheumatol; 1999 Oct; 26(10):2168-72. PubMed ID: 10529134
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Modification of B-cell precursor frequencies by systemic photochemotherapy (PUVA) in patients with systemic scleroderma].
    Kunzelmann V; Brenke A; Fetscher I; Lukowsky A; Leschik G; Adrian K; Sönnichsen N
    Z Arztl Fortbild (Jena); 1994 Aug; 88(7-8):519-24. PubMed ID: 7856255
    [No Abstract]   [Full Text] [Related]  

  • 35. [Clinico-immunologic shift in systemic scleroderma].
    Drampian FS; Grigorian EG; Aznaurian AV
    Vrach Delo; 1971 Apr; 7():91-4. PubMed ID: 5140143
    [No Abstract]   [Full Text] [Related]  

  • 36. [Case of systemic scleroderma with atypical clinical course].
    Sadowska H; Kuczewska-Stanecka K; Kabulski Z
    Wiad Lek; 1980 Dec; 33(23):1903-7. PubMed ID: 7245752
    [No Abstract]   [Full Text] [Related]  

  • 37. Evidence of microvascular injury in scleroderma and systemic lupus erythematosus: quantitative study of the microvascular bed.
    Norton WL; Hurd ER; Lewis DC; Ziff M
    J Lab Clin Med; 1968 Jun; 71(6):919-33. PubMed ID: 5654777
    [No Abstract]   [Full Text] [Related]  

  • 38. [Pathology forum. XL. Generalized progressive scleroderma].
    Lederer B; Huth K; Beneke G
    Med Welt; 1968 Sep; 37():1989-93. PubMed ID: 5712121
    [No Abstract]   [Full Text] [Related]  

  • 39. Antibody formation in porcine fetuses.
    Bourne FJ; Curtis J; Johnson RH; Collings DF
    Res Vet Sci; 1974 Mar; 16(2):223-7. PubMed ID: 4830985
    [No Abstract]   [Full Text] [Related]  

  • 40. Diagnostic criteria of dermatomyositis.
    Jablońska S
    Pol Med J; 1966; 5(6):1472-83. PubMed ID: 5973047
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.